Keytruda Qlex, a subcutaneous formulation, is FDA-approved for solid tumors in patients 12 and older, offering an alternative to intravenous administration. Study MK-3475A-D77 showed comparable ...
IO Biotech (NASDAQ:IOBT) announced on Monday that patients with skin tumors who received its lead cancer vaccine candidate, Cylembio, with Merck’s (NYSE:MRK) anti-PD-1 therapy, Keytruda, lived longer ...
New KEYTRUDA indications are expected to preserve Merck's top line, significantly aided by the high single-digit Animal Health/Livestock and the triple-digit Winrevair revenue growth in FY2025.
Sept 19 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's (MRK.N), opens new tab blockbuster cancer therapy Keytruda that can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results